Contraceptives – Time to become effective (if not used on the first day of period):
Immediate: IUD
2 days: Progestin-only pill (POP)
7 days: Combined oral contraceptive (COC), injection, implant, intrauterine system (IUS)

Intrauterine contraceptive devices include copper IUDs and levonorgestrel-releasing IUS. Both are over 99% effective. The IUD prevents fertilization by decreasing sperm motility, while the IUS prevents endometrial proliferation and thickens cervical mucus. Potential problems include heavier periods with IUDs and initial bleeding with the IUS. There is a small risk of uterine perforation, ectopic pregnancy, and infection. New IUS systems, such as Jaydess® and Kyleena®, have smaller frames and less levonorgestrel, resulting in lower serum levels and different rates of amenorrhea.

Common Causes of Cataracts and Their Associated Symptoms

Cataracts are a common eye condition that can cause visual impairment. While ageing is the most common cause, there are several other factors that can contribute to cataract development. Here are some of the common causes of cataracts and their associated symptoms:

1. Thyrotoxicosis: This condition involves excess synthesis and secretion of thyroid hormones, leading to the hypermetabolic condition of thyrotoxicosis. Symptoms include sympathetic activation in younger patients and cardiovascular symptoms and unexplained weight loss in older patients. Approximately 50% of patients with Graves-thyrotoxicosis have mild thyroid ophthalmopathy, which can cause periorbital edema, conjunctival edema, poor lid closure, extraocular muscle dysfunction, and proptosis.

2. Diabetes mellitus: Patients with diabetes are at risk of developing several ophthalmic complications, including cataracts. Epidemiological studies have shown that cataracts are the most common cause of visual impairment in patients with older-onset diabetes. Hyperglycemia is associated with loss of lens transparency, and rapid decline of serum glucose levels in patients with marked hyperglycemia may induce temporary lens opacification and swelling.

3. Myotonic dystrophy: This chronic genetic disorder affects muscle function and can cause gradually worsening muscle atrophy and weakness. Other symptoms include cataracts, intellectual disability, and heart conduction abnormalities. Myotonic dystrophy may cause a cortical cataract with a blue dot appearance or a posterior subcapsular cataract.

4. Rubella: Congenital cataracts are usually diagnosed at birth and can be associated with ocular abnormalities, trauma, or intrauterine infection, particularly rubella. Congenital rubella infection may result in growth delay, learning disability, hearing loss, congenital heart disease, and eye, endocrinological, and neurological abnormalities.

5. Hypoparathyroidism: This condition is characterized by hypocalcemia, hyperphosphatemia, and low or inappropriately normal levels of parathyroid hormone. Patients may present with hypocalcemia, mental changes, and neuromuscular excitability or tetany. Anatomical abnormalities, although not readily apparent, include deposition of calcium in soft tissues, including intracranial calcifications and cataract formation.

In addition to these causes, cataracts can also be caused by trauma

First-Line Treatment for Constipation in Children: Macrogol (Movicol)

When a child is diagnosed with constipation and secondary causes have been ruled out, treatment can be initiated. The first-line treatment recommended by NICE is macrogol, which is available as Movicol Paediatric Plain or Movicol depending on the child’s age. The dose is escalated until regular and good consistency stools are achieved. However, it is important to check for faecal impaction before starting maintenance treatment. Suppositories and enemas should not be routinely used in primary care. If macrogol is not tolerated or if there is a particularly hard stool, a stool softener such as lactulose can be used. A stimulant laxative such as senna can also be used as an alternative to macrogol.

When metronidazole and ethanol are taken together, it can result in a disulfiram-like reaction, which can cause symptoms such as flushing in the head and neck, nausea, vomiting, sweating, headaches, and palpitations. Additionally, alcohol consumption should be avoided when taking cefoperazone, a cephalosporin, as it can also lead to a disulfiram-like reaction.

Metronidazole is an antibiotic that functions by producing reactive cytotoxic metabolites within bacteria. This medication can cause adverse effects such as a disulfiram-like reaction when combined with alcohol and an increased anticoagulant effect when taken with warfarin.

For reducing the risk of stroke in patients with atrial fibrillation (AF), the first-line anticoagulation should be a direct oral anticoagulant (DOAC) such as rivaroxaban. This recommendation is based on a scenario where a patient is found to have AF during a wellbeing check and requires anticoagulation due to the increased risk of thrombosis. Aspirin is not the correct choice as it is an antiplatelet and not an anticoagulant. While dalteparin and enoxaparin are low molecular weight heparins that are often used for VTE prophylaxis, DOACs are preferred first-line for stroke risk reduction in AF. Patients often prefer DOACs as they are available in tablet form.

NICE recommends using the CHA2DS2-VASc score to determine the need for anticoagulation in patients with any history of AF. The ORBIT scoring system should be used to assess bleeding risk, but anticoagulation should not be withheld solely on the grounds of age or risk of falls. DOACs are now recommended as the first-line anticoagulant for patients with AF, with warfarin used second-line if a DOAC is contraindicated or not tolerated. Aspirin is not recommended for reducing stroke risk in patients with AF.

Patients who have recently started treatment are commonly affected by neuroleptic malignant syndrome, which can lead to renal failure due to rhabdomyolysis.

Understanding Neuroleptic Malignant Syndrome

Neuroleptic malignant syndrome is a rare but serious condition that can occur in patients taking antipsychotic medication. It can also happen with dopaminergic drugs used for Parkinson’s disease. The exact cause of this condition is unknown, but it is believed that dopamine blockade induced by antipsychotics triggers massive glutamate release, leading to neurotoxicity and muscle damage. Symptoms of neuroleptic malignant syndrome typically appear within hours to days of starting an antipsychotic and include fever, muscle rigidity, autonomic lability, and agitated delirium with confusion.

A raised creatine kinase is present in most cases, and acute kidney injury may develop in severe cases. Management of neuroleptic malignant syndrome involves stopping the antipsychotic medication and transferring the patient to a medical ward or intensive care unit. Intravenous fluids may be given to prevent renal failure, and dantrolene or bromocriptine may be used in selected cases. It is important to differentiate neuroleptic malignant syndrome from serotonin syndrome, which has similar symptoms but is caused by excessive serotonin activity.

In summary, neuroleptic malignant syndrome is a rare but potentially life-threatening condition that can occur in patients taking antipsychotic medication or dopaminergic drugs. Early recognition and management are crucial to prevent complications and improve outcomes.

The symptoms exhibited by this patient strongly indicate the presence of polymyalgia rheumatica, and thus, a one-week course of steroids should be administered to produce a significant improvement. Prescribing paracetamol for a month is unlikely to yield any noticeable relief. An MRI scan is not likely to aid in the diagnosis. Administering a prolonged course of steroids without periodic review is not recommended.

Polymyalgia Rheumatica: A Condition of Muscle Stiffness in Older People

Polymyalgia rheumatica (PMR) is a common condition that affects older people. It is characterized by muscle stiffness and elevated inflammatory markers. Although it is closely related to temporal arteritis, the underlying cause is not fully understood, and it does not appear to be a vasculitic process. PMR typically affects patients over the age of 60 and has a rapid onset, usually within a month. Patients experience aching and morning stiffness in proximal limb muscles, along with mild polyarthralgia, lethargy, depression, low-grade fever, anorexia, and night sweats.

To diagnose PMR, doctors look for raised inflammatory markers, such as an ESR of over 40 mm/hr. Creatine kinase and EMG are normal. Treatment for PMR involves prednisolone, usually at a dose of 15mg/od. Patients typically respond dramatically to steroids, and failure to do so should prompt consideration of an alternative diagnosis.

Once a child reaches the age of 16, they are considered competent to provide consent for treatment. In this case, the 16-year-old child can provide consent for the blood transfusion, but cannot refuse it. Therefore, the blood can be given as the child has provided consent. If the child were to refuse the treatment, the blood could still be given in their best interests without the consent of the child or their parents, using the Children Act 1989 and a High Court Order. However, in this particular case, such an order is not necessary. While some Jehovah witnesses may accept certain blood products, such as fresh frozen plasma or albumin, they may decline a complete blood transfusion. However, this is not appropriate in this situation. It may be advisable to contact the hospital liaison representative, but as the child is of age and understands the situation, they are able to provide consent for the treatment.

Understanding Consent in Children

The issue of consent in children can be complex and confusing. However, there are some general guidelines to follow. If a patient is under 16 years old, they may be able to consent to treatment if they are deemed competent. This is determined by the Fraser guidelines, which were previously known as Gillick competence. However, even if a child is competent, they cannot refuse treatment that is deemed to be in their best interest.

For patients between the ages of 16 and 18, it is generally assumed that they are competent to give consent to treatment. Patients who are 18 years or older can consent to or refuse treatment.

When it comes to providing contraceptives to patients under 16 years old, the Fraser Guidelines outline specific requirements that must be met. These include ensuring that the young person understands the advice given by the healthcare professional, cannot be persuaded to inform their parents, is likely to engage in sexual activity with or without treatment, and will suffer physical or mental health consequences without treatment. Ultimately, the young person’s best interests must be taken into account when deciding whether to provide contraceptive advice or treatment, with or without parental consent.

In summary, understanding consent in children requires careful consideration of age, competence, and best interests. The Fraser Guidelines provide a useful framework for healthcare professionals to follow when providing treatment and advice to young patients.

According to NICE (2017) guidelines, patients with asthma should be prescribed a SABA as the first step of treatment. However, if a patient experiences symptoms three or more times per week or night waking, they should also be prescribed a low-dose ICS inhaler as the second step of treatment. This is also necessary for patients who have had an acute exacerbation requiring oral corticosteroids in the past two years. In this case, the patient’s symptoms are not well-controlled with a SABA alone, and she experiences frequent symptoms and night waking. Therefore, she requires a low-dose ICS inhaler, and the only option available is budesonide.

Adding a salmeterol inhaler is not appropriate at this stage, as LABAs are only used as the fourth step of treatment if a patient is not controlled with a SABA, low-dose ICS, and a trial of LTRAs. Similarly, adding montelukast and a beclomethasone inhaler is not appropriate, as LTRAs are only added if a patient is still not controlled on a low-dose ICS and a SABA. However, it may be appropriate to trial beclomethasone without montelukast.

Continuing with the current salbutamol-only treatment is not appropriate, as the patient’s asthma is poorly controlled, which increases the risk of morbidity and mortality. Regular salbutamol has no role in the management of asthma, as it does not improve outcomes and may even worsen them by downregulating beta receptors that are important for bronchodilation.

The management of asthma in adults has been updated by NICE in 2017, following the 2016 BTS guidelines. One of the significant changes is in ‘step 3’, where patients on a SABA + ICS whose asthma is not well controlled should be offered a leukotriene receptor antagonist instead of a LABA. NICE does not follow the stepwise approach of the previous BTS guidelines, but to make the guidelines easier to follow, we have added our own steps. The steps range from newly-diagnosed asthma to SABA +/- LTRA + one of the following options, including increasing ICS to high-dose, a trial of an additional drug, or seeking advice from a healthcare professional with expertise in asthma. Maintenance and reliever therapy (MART) is a form of combined ICS and LABA treatment that is only available for ICS and LABA combinations in which the LABA has a fast-acting component. It should be noted that NICE does not recommend changing treatment in patients who have well-controlled asthma simply to adhere to the latest guidance. The definitions of what constitutes a low, moderate, or high-dose ICS have also changed, with <= 400 micrograms budesonide or equivalent being a low dose, 400 micrograms - 800 micrograms budesonide or equivalent being a moderate dose, and > 800 micrograms budesonide or equivalent being a high dose for adults.

Different Types of Lung Diseases and their Spirometry Patterns

Scoliosis and Lung Function
Severe scoliosis can affect the respiratory muscles and the natural movements of the thoracic cage, leading to a restrictive pattern in pulmonary function tests. This can prevent the lungs from expanding correctly, compromising their function.

Cystic Fibrosis and Lung Function
In early stage cystic fibrosis, the presence of inflammation and thick secretions in the airways can cause an obstructive pattern in spirometry tests. As damage to the lung tissue occurs, a restrictive component can also develop, resulting in a combined obstructive and restrictive pattern.

Emphysema and Lung Function
Emphysema is a type of obstructive lung disease characterized by abnormal and irreversible enlargement of air spaces and alveolar wall destruction. This leads to airflow limitation and a spirometry pattern typical of obstructive lung disease.

Asthma and Lung Function
Asthma is an inflammatory disorder of the airways that causes hyperresponsiveness and constriction of the airways in response to various stimuli. This leads to airflow limitation and a spirometry pattern typical of obstructive lung disease.

Bronchiectasis and Lung Function
Bronchiectasis is characterized by abnormal and irreversible dilatation of the bronchial walls, leading to accumulation of secretions and recurrent inflammation of the airways. This produces an obstructive pattern in pulmonary function tests.

In summary, different types of lung diseases can affect lung function in various ways, leading to different spirometry patterns. Understanding these patterns can help in the diagnosis and management of these conditions.